James Crowe
Faculty Member
Last active: 3/31/2020

Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein.

Bates JT, Keefer CJ, Slaughter JC, Kulp DW, Schief WR, Crowe JE
Virology. 2014 454-455: 139-44

PMID: 24725940 · PMCID: PMC4004766 · DOI:10.1016/j.virol.2014.02.010

MeSH Terms (11)

Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antibodies, Neutralizing Drug Resistance, Viral Humans Kinetics Mutation Palivizumab Protein Binding Respiratory Syncytial Viruses Viral Fusion Proteins

Connections (1)

This publication is referenced by other Labnodes entities: